Clinical Trial

Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Name: Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer — clinical trial record (NCT06547385)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.

Trial Details

NCT Number	NCT06547385
Lead Sponsor	Ono Pharmaceutical Co., Ltd.
Conditions	Colorectal Cancer
Enrollment	40 participants
Start Date	2021-01-13
Primary Completion	2027-10-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-09